The efficacy of fetal fibronectin testing in minimising hospital admissions, length of hospital stay and cost savings in women presenting with symptoms of pre-term labour

Journal of Obstetrics and Gynaecology

Volumn 30, Issue 8, 2010, Pages 768-773

  Dutta, D ^a   Norman, J E ^b  

^a CROSSHOUSE HOSPITAL   (United Kingdom)

^b UNIVERSITY OF EDINBURGH   (United Kingdom)

Author keywords

Cervical length; Fetal fibronectin; Pre term labour

Indexed keywords

CORTICOSTEROID; FIBRONECTIN; UTERUS SPASMOLYTIC AGENT;

CERVICAL LENGTH MEASUREMENT; HEALTH CARE COST; HEALTH ECONOMICS; HEALTH SERVICE; HOSPITAL ADMISSION; HUMAN; LENGTH OF STAY; MEDICAL LITERATURE; MEDLINE; PREMATURE LABOR; PRIORITY JOURNAL; REVIEW; TRANSVAGINAL ECHOGRAPHY;

ADRENAL CORTEX HORMONES; CERVICAL LENGTH MEASUREMENT; FEMALE; FIBRONECTINS; HUMANS; LENGTH OF STAY; OBSTETRIC LABOR, PREMATURE; PATIENT ADMISSION; PREGNANCY; TOCOLYTIC AGENTS;

EID: 78649918727     PISSN: 01443615     EISSN: 13646893     Source Type: Journal    
DOI: 10.3109/01443615.2010.518259     Document Type: Review

References (23)

1. Abenhaim HA, Morin L, Benjamin A. 2005. Does availability of fetal fibronectin testing in the management of threatened pre-term labor affect the utilization of hospital resources? Journal of Obstetrics and Gynecology Canada 27:689-694.
2. Chuileannain FN, Bell R, Brennecke S. 1998. Cervicovaginal fetal fibronectin testing in threatened pre-term labor-translating research findings into clinical practice. Australian and New Zealand Journal of Obstetrics and Gynaecology 38:399-402.
3. Foxman EF, Petr J. 2004. Use of the fetal fibronectin test in decisions to admit to hospital for pre-term labor. Clinical Chemistry 50:663.
4. Garcia Alonso LA, Ayala Mendez JA, Jimenez Solis GAG, Diaz Cueto L. 2004. Economical impact of pre-term delivery management based on fetal fibronectin results. Gynecologia y Obstetricia de Mexico 72:385-393.
5. Giles W, Bisits A, Knox M, Madsen G, Smith R. 2000. The effect of fetal fibronectin testing on admissions to a tertiary maternalfetal medicine unit and cost savings. American Journal of Obstetrics and Gynecology 182:439-442.
6. Gomez R, Romero R, Medina L, Nien JK, Chaiworapongsa T, Carstens M. 2005. Cervicovaginal fibronectin improves the prediction of pre-term delivery based on sonographic cervical length in patients with pre-term uterine contractions and intact membranes. American Journal of Obstetrics and Gynecology 192:350-359.
7. Grobman WA, Welshman EE, Calhoun EA. 2004. Does fetal fibronectin use in the diagnosis of pre-term labor affect physician behaviour and health care costs? A randomized trial. American Journal of Obstetrics and Gynecology 191:235-240.
8. Hincz P, Wilczynski J, Kozarzewski M, Szaflik K. 2002. Two-step test: the combined use of fetal fibronectin and sonographic examination of the uterine cervix for prediction of pre-term delivery in symptomatic patients. Acta Obstetricia et Gynecologica Scandinavica 81:58-63.
9. Honest H, Bachmann LM, Gupta JK, Kleijnen J, Khan KS. 2002. Accuracy of cervicovaginal fetal fibronectin test risk of spontaneous pre-term birth: systematic review. British Medical Journal 325:301.
10. Incerti M, Ghidini A, Korker V, Pezzullo JC. 2007. Performance of cervicovaginal fetal fibronectin in a community hospital setting. Archives of Gynaecology and Obstetrics 275:347-351.
11. ISD. 2005. Information and Statistics Division NS: Birth and babies, 2005. Nova Scotia: ISD.
12. Joffe GM, Jacques D, Bemis-Heys R, Skram B, Shelbirne P. 1999. Impact of the fetal fibronectin assay on admissions for pre-term labor. American Journal of Obstetrics and Gynecology 180:581-586.
13. Lowe MP, Zimmerman B, Hansen W. 2004. Prospective randomized controlled trial of fetal fibronectin on pre-term labor management in a tertiary care centre. American Journal of Obstetrics and Gynecology 190:358-362.
14. Mozurkewich EL, Naglie G, Krahn MD, Hayashi RH. 2000. A cost effectiveness analysis. American Journal of Obstetrics and Gynecology 182:1589-1598.
15. Ness A, Visintine J, Ricci E, Berghella V. 2007. Does knowledge of cervical length and fetal fibronectin affect management of women with threatened pre-term labour? A randomized trial. American Journal of Obstetrics and Gynecology 197:426-427.
16. Parry E, Singh TG, Fiona DN. 2006. Improved management in threatened pre-term labor with rapid fetal fibronectin testing. Australian and New Zealand Journal of Obstetrics and Gynaecology 46:240-241.
17. Plaut MM, Smith W, Kennedy K. 2003. The impact of a rapid test on the treatment of women with pre-term labor symptoms. American Journal of Obstetric and Gynecology 188:1588-1593.
18. RCOG. 2002. Tocolytic drugs for women in pre-term labour. Clinical Guideline 1B. London: Royal College of Obstetricians and Gynaecologists.
19. Rizzo G, Capponi A, Arduini D, Lorido C, Romanini C. 1996. The value of fetal fibronectin in cervical and vaginal secretions and of ultrasonographic examination of the uterine cervix in predicting premature delivery for patients with pre-term labour and intact membranes. American Journal of Obstetrics and Gynecology 175:1146-1151.
20. Rozenberg P. 1998. New markers of the risk of pre-term delivery. Bulletin de l'Academie Nationale de Medecine 182:1455-1468.
21. Samarina MA, Musad LC, Boswel RD. 2006. Fetal Fibronectin assay may reduce management cost of pre-term labor; an interval analysis. Pathology 38:473-474.
22. Schmitz T, Maillard F, Bessard-Bacquaert S, Kayem G, Fulla Y, Cabrol D et al. 2006. Selective use of fetal fibronectin detection after cervical length measurement to predict spontaneous preterm delivery in women with pre-term labour. American Journal of Obstetrics and Gynecology 194:138-143.
23. Swamy GK, Simhan HN, Gammill HS, Heine RP. 2005. Clinical utility of fetal fibronectin for predicting pre-term birth. Journal of Reproductive Medicine 50:851-856.